Open for Enrollment
R5458-ONC-2246 / Linker MM5: An open-label, randomized Phase 3 study comparing linvoseltamab monotherapy and linvoseltamab plus carfilzomib with standard-of-care combination regimens in patients with RRMM
CENTERS
- Izmir University of Economics Faculty of Medicine Medical Point Hospital
- Ankara University Faculty of Medicine Cebeci Hospital
- Medical Park Bahçelievler Hospital
- Ege University Faculty of Medicine Hospital
- Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital
- Dokuz Eylül University Faculty of Medicine
- Istanbul Florence Nightingale Hospital
- Gazi University Faculty of Medicine
Open for Enrollment
TRIlogy-7: Protocol code “79635322MMY3004” – A Phase 3 randomized study comparing the combination of Ramantamig and Daratumumab versus investigator’s choice of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) or Daratumumab, Lenalidomide and Dexamethasone (DRd) in participants with newly diagnosed multiple myeloma not planned for hematopoietic stem cell transplantation as initial therapy.
CENTERS
- Liv Hospital Ankara
- Ankara University Cebeci Hospital
- Memorial Antalya Hospital
- Medipol University Hospital
- Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital
- İstanbul Florence Nightingale Hospital
- Ondokuz Mayıs University Faculty of Medicine
- Ankara Etlik City Hospital
- Marmara University Pendik Training and Research Hospital
- Akdeniz University Faculty of Medicine
- İzmir Tinaztepe University Private Galen Hospital
- Koç University Hospital
Open for Enrollment
Emn39: A randomized, open-label, controlled Phase 3 study comparing Daratumumab, Lenalidomide and Dexamethasone induction versus Linvoseltamab in newly diagnosed transplant-ineligible multiple myeloma patients.
PARTICIPATING CENTERS
- Ankara Liv Hospital
- Ege University Faculty of Medicine Hospital
- Gülhane Training and Research Hospital
- Ankara Faculty of Medicine Cebeci Hospital
Open for Enrollment
TRIlogy-5: A Phase 3 randomized study comparing JNJ-79635322 versus Teclistamab in participants with relapsed or refractory multiple myeloma after 1 to 3 prior lines of therapy, including an anti-CD38 antibody and lenalidomide
PARTICIPATING CENTERS
- Ankara University Faculty of Medicine
- İstanbul Medipol Mega University Hospital
- Memorial Antalya Hospital
- Ankara LIV Hospital
- İzmir Tınaztepe University Hospital
- Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital
- Ankara Etlik City Hospital
- GATA Haydarpaşa Training and Research Hospital
- Samsun Ondokuz Mayıs University Faculty of Medicine Hospital
- Florence Nightingale Hospitals
- Mersin University Faculty of Medicine Hospital
Open for Enrollment
QUINTESSENTIAL-2: A Phase 3, randomized, open-label, multicenter study to compare the efficacy and safety of Arlocabtagene Autoleucel (BMS-986393), a GPRC5D-directed CAR-T cell therapy, with standard-of-care regimens in adult participants with relapsed or refractory multiple myeloma previously exposed to lenalidomide.
PARTICIPATING CENTERS
- Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital
Upcoming Enrollment
SELICAR: A Phase I Trial Evaluating the Efficacy of Selinexor, Carfilzomib, and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients Who Have High-Risk Features and/or Do Not Achieve at Least a Very Good Partial Response (VGPR) After Transplantation (SELICAR)
Upcoming Enrollment
CA204-185: Continued treatment for subjects who have participated in a previous protocol investigating elotuzumab
Upcoming Enrollment
M24-473: A Phase 2/3, multicenter, randomized, open-label study investigating the efficacy and safety of Etentamig (ABBV 383) versus Daratumumab, Cyclophosphamide, Bortezomib and Dexamethasone (Dara CyBorD) in newly diagnosed amyloid light-chain (AL) amyloidosis patients
PLANNED CENTERS
- Ankara Liv Hospital
- Ankara University Faculty of Medicine
- Ondokuz Mayıs University Faculty of Medicine
- Cerrahpaşa Faculty of Medicine
- Çapa Faculty of Medicine
Upcoming Enrollment
M22-538: Protocol title: A Phase 3, multicenter, randomized, open-label study evaluating the safety and efficacy of Etentamig in combination with Pomalidomide compared with current standard therapies in patients with relapsed or refractory multiple myeloma (2L+ RRMM)
Upcoming Enrollment
DREAMM-17: A Phase 1 study evaluating the pharmacokinetics and safety of Belantamab Mafodotin, Bortezomib and Dexamethasone (BVd) combination in multiple myeloma patients with moderate hepatic impairment
Upcoming Enrollment
DREAMM-16: A Phase 2, multicenter, randomized, open-label study evaluating the safety, efficacy and pharmacokinetics of alternative and approved dosing regimens of Belantamab Mafodotin in combination with Bortezomib and Dexamethasone (BVd) in patients with relapsed or refractory multiple myeloma
Upcoming Enrollment
DREAM 20: A Phase 1/2 open-label, multicenter, dose-escalation and expansion study to examine the safety, tolerability and clinical activity of belantamab as monotherapy and in combination with other treatments in patients with multiple myeloma
PLANNED CENTERS
- Ege University Hospital
- Koç University Hospital
- Kayseri City Hospital
- Ankara Bilkent City Hospital
- İstanbul University-Cerrahpaşa Cerrahpaşa Faculty of Medicine Hospital
- Ankara University Faculty of Medicine (Hospital)
- Ankara Liv Hospital
Follow-up Period
TRIlogy-3: A Phase 2, open-label study evaluating JNJ-79635322 in patients with relapsed or refractory multiple myeloma (RRMM) who have received at least 3 prior lines of therapy (including a proteasome inhibitor [PI], an immunomodulatory drug [IMiD] and an anti-CD38 antibody)
PARTICIPATING CENTERS
- Ankara LIV Hospital
- Ankara University Faculty of Medicine Hospital
- İstanbul Medipol Mega University Hospital
- Memorial Antalya Hospital
- İstanbul Florence Nightingale Hospital
- University of Health Sciences Göztepe Prof. Dr. Süleyman Yalçın City Hospital
- Ankara Etlik City Hospital
- Sakarya University Training and Research Hospital
Follow-up Period
MONUMENTAL6: A Phase 3 randomized study comparing Talquetamab plus Pomalidomide (Tal-P), Talquetamab plus Teclistamab (Tal-Tec), and investigator’s choice of Elotuzumab, Pomalidomide and Dexamethasone (EPd) or Pomalidomide, Bortezomib and Dexamethasone (PVd) in participants with relapsed or refractory myeloma who have received 1 to 4 prior lines of therapy including an anti-CD38 antibody and lenalidomide
PARTICIPATING CENTERS
- Ankara Liv Hospital
- Samsun 19 Mayıs University Hospital
- Medipol Hospital
- Ankara Faculty of Medicine Cebeci Hospital
- Pamukkale University Hospital
Follow-up Period
IM048-022 Excaliber Maintenance: A Phase 3, two-stage, randomized, multicenter, controlled, open-label study comparing Iberdomide maintenance therapy versus Lenalidomide maintenance therapy after autologous stem cell transplantation (ASCT) in participants with newly diagnosed multiple myeloma (NDMM)
PARTICIPATING CENTERS
- Ankara Liv Hospital
- Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital
- Dokuz Eylül University Faculty of Medicine
- Ankara Gazi Hospital
- Erciyes University Faculty of Medicine
- Ege University Faculty of Medicine
- Marmara University Faculty of Medicine
- Ondokuz Mayıs University Faculty of Medicine
- Ankara Faculty of Medicine Cebeci Hospital
Follow-up Period
CA057-001 SUCCESSOR: A Phase 3, two-stage, randomized, multicenter, open-label study comparing CC-92480, Bortezomib and Dexamethasone (480Vd) versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in patients with relapsed or refractory multiple myeloma (RRMM) (CA057-001)
PARTICIPATING CENTERS
- Ankara Liv Hospital
- Kayseri Erciyes University
- Ankara Faculty of Medicine Cebeci Hospital
- Samsun 19 Mayıs University Hospital
- İstanbul Çapa Training and Research Hospital
Follow-up Period
Majestec-7: A Phase 3 randomized study comparing Teclistamab in combination with Daratumumab SC and Lenalidomide (Tec-DR) versus Daratumumab SC, Lenalidomide and Dexamethasone (DRd) in participants with newly diagnosed multiple myeloma who are ineligible for or not intended for autologous stem cell transplantation as first-line therapy
PARTICIPATING CENTERS
- Ankara Liv Hospital
- Ankara Faculty of Medicine Cebeci Hospital
- Dokuz Eylül University Faculty of Medicine
- Ondokuz Mayıs University
- İstanbul University Faculty of Medicine
- Medipol University Hospital
Follow-up Period
EMN30 (MAJESTTEC-4): A Phase 3 study comparing Teclistamab in combination with Lenalidomide versus Lenalidomide alone as maintenance therapy after autologous stem cell transplantation in patients with newly diagnosed multiple myeloma
PARTICIPATING CENTERS
- Ankara Liv Hospital
- Ankara Faculty of Medicine Cebeci Hospital
- Erciyes University Faculty of Medicine
- İstanbul Florence Nightingale Hospital
Follow-up Period
CC-220-MM-002 Excaliber Relapsed: A Phase 3, two-stage, randomized, multicenter, open-label study comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) versus Daratumumab, Bortezomib and Dexamethasone (DVd) in patients with relapsed or refractory multiple myeloma
PARTICIPATING CENTERS
- Ankara Liv Hospital
- Ankara Faculty of Medicine Cebeci Hospital
- Erciyes University Faculty of Medicine
- Dokuz Eylül University Faculty of Medicine
- Ege University Faculty of Medicine
- Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital
- Marmara University Faculty of Medicine
- Gazi University Faculty of Medicine
- Ondokuz Mayıs University Faculty of Medicine
Follow-up Period
Monumental-3: A Phase 3 randomized study comparing Talquetamab SC in combination with Daratumumab SC and Pomalidomide (Tal-DP) or Talquetamab SC in combination with Daratumumab SC (Tal-D) versus Daratumumab SC, Pomalidomide and Dexamethasone (DPd) in participants with relapsed or refractory multiple myeloma who have received at least 1 prior line of therapy
PARTICIPATING CENTERS
- Ankara Liv Hospital
- Gazi University Faculty of Medicine
- Ondokuz Mayıs University Faculty of Medicine
- İstanbul University Faculty of Medicine
- Pamukkale University Hospital
- Antalya Memorial Hospital
- Gata Training and Research Hospital
- Hacettepe University Faculty of Medicine
- Dokuz Eylül University Faculty of Medicine
- Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital
- Erciyes University Faculty of Medicine
Follow-up Period
Majestec-9: A Phase 3 randomized study comparing Teclistamab monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib Dexamethasone (Kd) combination in patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of therapy including an anti-CD38 monoclonal antibody and lenalidomide
PARTICIPATING CENTERS
- Ankara Liv Hospital
- Medipol Mega University Hospital
- Samsun 19 Mayıs University Hospital
- Antalya Training and Research Hospital
- Gülhane Ankara University Faculty of Medicine
- Pamukkale University
Follow-up Period
Dreamm10: A Phase 3, randomized, open-label study comparing Belantamab Mafodotin in combination with Lenalidomide and Dexamethasone versus Daratumumab, Lenalidomide and Dexamethasone in newly diagnosed multiple myeloma patients who are ineligible for autologous stem cell transplantation (TI-NDMM)
PARTICIPATING CENTERS
- Ankara Liv Hospital
- Ankara Faculty of Medicine Cebeci Hospital
- İstanbul Florence Nightingale Hospital
- Kocaeli University Faculty of Medicine
- Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital
- Ege University Faculty of Medicine
- Mersin Medical Park Hospital
Follow-up Period
AFFIRM-AL: A Phase 3, randomized, multicenter, double-blind, placebo-controlled efficacy and safety study comparing Birtamimab plus standard of care versus Placebo plus standard of care in Mayo Stage IV patients with light-chain (AL) amyloidosis
PARTICIPATING CENTERS
- Dokuz Eylül University Faculty of Medicine
- Private Anadolu Medical Center
- Akdeniz University Faculty of Medicine
- Aydın Adnan Menderes University
- Dr. Abdurrahman Yurtaslan
- Medipol Mega University Hospital
- Erciyes University Faculty of Medicine
- Ege University Faculty of Medicine
- Ankara Faculty of Medicine Cebeci Hospital
- İstanbul Florence Nightingale Hospital
- Gazi University Hospital
- Adana Başkent University Hospital
Study Completed
CANOVA: Phase 3 study comparing Venetoclax and Dexamethasone versus Pomalidomide and Dexamethasone
Study Completed
MAGNETISM 5: Phase 3 study comparing Elranatamab (PF-06863135) monotherapy versus Elranatamab + Daratumumab
Study Completed
MAGNETISM 7: Phase 3 study comparing Elranatamab versus Lenalidomide after autologous stem cell transplantation
Study Completed
IMROZ: Phase 3 study evaluating the clinical benefit of Isatuximab (SAR650984) in combination with VRd
Study Completed
PERSEUS: Phase 3 study comparing DVRd and VRd regimens
Study Completed
ANTARES (EMN19): Daratumumab combination in MM patients presenting with extramedullary disease
Study Completed
DREAMM 8: Efficacy study of Belantamab Mafodotin versus Pomalidomide + Bortezomib and Dexamethasone
Study Completed
CEPHEUS: Phase III study comparing D-VRd versus VRd regimens in untreated MM patients
Study Completed
SMM3001: Phase 3 study of subcutaneous Daratumumab in high-risk asymptomatic multiple myeloma patients
Study Completed
AMY3001 (ANDROMEDA): Phase 3 study of Daratumumab in combination with CyBorD in patients with systemic AL amyloidosis
Study Completed
CC-4047-MM-007: Efficacy study of Pomalidomide (POM), Bortezomib (BTZ) and low-dose Dexamethasone in volunteers with relapsed or refractory MM
Ixazomib Program – Study Completed
Efc15951 IRAKLIA: A randomized, Phase 3, open-label study evaluating subcutaneous versus intravenous Isatuximab in combination with Pomalidomide and Dexamethasone in adult volunteers diagnosed with relapsed and/or refractory multiple myeloma (RRMM)
Study Completed
Ixazomib Program – C16010: Phase 3 study comparing oral MLN9708 plus Lenalidomide and Dexamethasone versus Placebo plus Lenalidomide and Dexamethasone in adult patients with relapsed and/or refractory multiple myeloma
Ixazomib Program – C16011: Phase 3 study evaluating the safety and efficacy of MLN9708 plus Dexamethasone or physician’s choice of treatment in patients with relapsed or refractory systemic light-chain amyloidosis
Ixazomib Program – C16019: A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral MLN9708 Maintenance Therapy in Patients With Multiple Myeloma Following Autologous Stem Cell Transplant
Ixazomib Program – C16021: Phase 3 study of oral Ixazomib maintenance therapy after initial therapy in newly diagnosed multiple myeloma patients not treated with stem cell transplantation
Ixazomib Program – C16029: Phase 2/3 study comparing oral Ixazomib/Dexamethasone versus oral Pomalidomide/Dexamethasone in relapsed and/or refractory multiple myeloma
Study Completed
CA204004: Phase 3 study of Lenalidomide/Dexamethasone with or without Elotuzumab in relapsed or refractory multiple myeloma
Study Completed
54767414MMY3004 (CASTOR): Phase 3 study comparing Daratumumab, Bortezomib and Dexamethasone (DVd) versus Bortezomib and Dexamethasone (Vd) in patients with relapsed or refractory multiple myeloma
Study Completed
MMY3013-APOLLO: Phase 3 study comparing Pomalidomide plus Dexamethasone with or without Daratumumab in volunteers with relapsed or refractory multiple myeloma who have previously received at least one line of therapy with Lenalidomide and a proteasome inhibitor
Study Completed
MAJESTEC-3: Phase 3 randomized study comparing Teclistamab in combination with Daratumumab subcutaneous (SC) (Tec-Dara) versus Daratumumab SC, Pomalidomide and Dexamethasone (DPd) or Daratumumab SC, Bortezomib and Dexamethasone (DVd) in patients with relapsed or refractory multiple myeloma
PREVIOUSLY PARTICIPATING CENTERS
- Dokuz Eylül University Faculty of Medicine
- Ankara University Faculty of Medicine
- İstanbul Medipol Mega Hospital
- Ondokuz Mayıs University Faculty of Medicine
- İstanbul Çapa Faculty of Medicine
Study CompletedEMN02/HOVON95: Phase III study investigating VMP versus High-Dose Melphalan (HDM) treatment in newly diagnosed MM patients
Study CompletedCentaurus (SMM2001): Phase 2 study evaluating 3 Daratumumab dosing schedules in asymptomatic multiple myeloma patients
Study CompletedCANDOR: Phase 3 study comparing Carfilzomib, Dexamethasone and Daratumumab versus Carfilzomib and Dexamethasone
Study CompletedEFC14335-ICARIA: Phase 3 study of Isatuximab (SAR650984) in combination with Pomalidomide and low-dose dexamethasone
Study CompletedEMN11/HOVON114: Study of Carfilzomib and Dexamethasone Induction/Maintenance Therapy in combination with Pomalidomide
Study CompletedIKEMA – EFC15246: Phase 3 study of Isatuximab, Carfilzomib and Dexamethasone combination in relapsed/refractory MM patients
Study CompletedAlcyone: Phase 3 comparative study of D-VMP versus VMP in patients ineligible for high-dose therapy
Study Completed115523 (ZOSTER-002): Phase III safety study of Herpes Zoster vaccine in hematopoietic stem cell transplant recipients
Study CompletedAMG 162 (Denosumab): Comparative study of Denosumab versus Zoledronic Acid in the treatment of bone disease
Study CompletedCC4047-MM010: Single-arm study of Pomalidomide in combination with low-dose dexamethasone
Study CompletedOptimized retreat (MARS): Phase 3 study of maintenance therapy after Bortezomib (VELCADE®) salvage therapy
Study CompletedOnyx 2012-005 (Clarion): Phase-3 study of KMP (Carfilzomib) vs VMP (Bortezomib) in newly diagnosed MM patients
Study CompletedH9S-MS-JDCG: Phase 2/3 Tabalumab study in combination with Bortezomib and Dexamethasone in multiple myeloma
Study CompletedCA204006: Phase 3 study of Elotuzumab with Lenalidomide/Dexamethasone in previously untreated MM patients
Study CompletedPANAROMA: Phase III study of Panobinostat, Bortezomib and Dexamethasone in relapsed MM patients
Study CompletedMM015: Phase III study of Lenalidomide, Melphalan and Prednisone combination in patients aged 65 and over
Study CompletedMMY2045: Efficacy study of Velcade combinations (Cyclophosphamide or Lenalidomide) in volunteers with refractory or relapsed MM
Study CompletedTKI258: Phase II study of TKI258 in patients with or without t(4;14) translocation
Study CompletedMMY2060: Phase 2 study evaluating the effect of VELCADE on myeloma-related bone disease
Study CompletedTurkish Myeloma Study Group MPT study: Phase III study of Thalidomide and Melphalan/Prednisolone combination therapy in newly diagnosed MM patients over 55 years of age